Prime Medicine

PRME

Market cap $1.03B

CAMBRIDGE, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences: H.C.

Prime Medicine, Inc. (NASDAQ:PRME ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:05 PM EDT Company Participants Allan Reine - CEO & Director Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Okay. Well, thanks, everybody, for joining us.

Prime Medicine, Inc. (NASDAQ:PRME ) Citi's Biopharma Back to School Conference September 2, 2025 4:45 PM EDT Company Participants Allan Reine - CEO & Director Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Vice President It's my pleasure to be hosting Prime Medicine for a fireside chat. I'm joined by Allan Reine, CEO of Prime as well as Greg Dearborn, Head of IR.

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: Citi's 2025 Biopharma Back to School Conference: Fireside chat on Tuesday, September 2, 2025, at 4:45 p.m.

PRME Revenue Misses by 73%

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.46 per share a year ago.

-- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions based on current dataset -- -- Completed follow-on offering, raising $144.2 million in gross proceeds and extending cash runway into 2027 --

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share.

CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 38,000,000 shares of its common stock at a public offering price of $3.30 per share.

CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of shares of its common stock. Prime Medicine also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of its common stock offered in the public offering. All of the shares of common stock in the proposed offering are to be sold by Prime Medicine. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.